Novartis Shares Plunge After Late-Stage Neuromuscular Drug Trial Fails

Novartis stock dropped sharply after announcing that its experimental treatment for a rare muscular disease missed its primary endpoint in a late-stage clinical trial. The failure marks the third consecutive development setback for the pharmaceutical giant, raising concerns over its future pipeline and investor confidence.

8 Sept, 05:48 — 8 Sept, 10:13

Post Share

Why this matters

Novartis’s heavy reliance on external acquisitions like Avidity has become a high-stakes strategy in an industry where internal R&D success rates are declining. Repeated late-stage failures threaten shareholder confidence, potentially impacting dividend sustainability and limiting capital for future innovation. Investors are closely watching whether this signals a temporary stumble or a fundamental shift in the company’s development capabilities.

Key entitiesNovartis del-desiran Avidity Biosciences Dyne Therapeutics Sarepta Therapeutics

The Story

What 10 sources agree on, dispute, and miss

What sources agree on

Novartis shares fell between 10% and 13% following the trial results
The failed candidate was del-desiran, a neuromuscular treatment
This represents the company’s third clinical trial setback in one week
Novartis previously acquired Avidity Biosciences for roughly $12 billion

Key claims4 agreed · 1 unverified

✓

Novartis shares declined between 10% and 13% on the day of the announcement

agreed·bloombergseeking-alphacnbc20-minuten

✓

The failed medication was named del-desiran

agreed·bloombergcnbcReuterswsj

✓

This trial failure marks Novartis's third clinical setback within a seven-day period

agreed·bloombergcnbcFT

The stock decline negatively impacted peer biotechnology companies including Dyne Therapeutics and Sarepta Therapeutics

unverified·seeking-alpha

✓

Novartis completed its acquisition of Avidity Biosciences for approximately $12 billion

agreed·bloomberg

Where they diverge

Strategic vs. operational framing of the failure

bloombergwsj

Frames the setback through the lens of capital allocation and the strategic risks of the $12B Avidity acquisition

FTcnbc

Emphasizes chronic pipeline weakness and repeated clinical misfires as signs of deeper R&D dysfunction

Market contagion emphasis

seeking-alpha

Highlights immediate spillover effects, noting how the drop dragged down peer biotechs like Dyne and Sarepta

Reutersmorningstar

Focuses exclusively on Novartis’s internal valuation and dividend implications without discussing sector-wide contagion

Coverage gaps

Specific regulatory next steps or potential FDA advisory committee discussions

ReportedFT

MissingbloombergcnbcReuters+1

Detailed breakdown of the $12B Avidity deal terms and integration status

Reportedbloomberg

MissingFTcnbcReuters+1

Coverage matrix

	Reuters	bloomberg	wsj	FT	cnbc	morningstar	index-hr	seeking-alpha	20-minuten	investing-com
Strategic vs. operational framing of the failure
Market contagion emphasis
Specific regulatory next steps or potential FDA advisory committee discussions
Detailed breakdown of the $12B Avidity deal terms and integration status

Covered Divergent Not mentioned

The Story

Analyzing sources…

Source Diversity

High (71/100)

10 sources33/33

Spectrum spread— 3/5 buckets covered17/33

Far L

Left2

Left (2)

cnbcindex-hr

Center6

Center (6)

bloombergFT20-minuteninvesting-comReutersmorningstar

Right2

Right (2)

seeking-alphawsj

Far R

Geographic diversity— 5 regions21/34

US6UK1Switzerland1Croatia1Intl1

Political spectrum

LeftCenterRight

index-hr

cnbc

bloomberg

20-minuten

investing-com

reuters

morningstar

seeking-alpha

wsj

Outlet rating This story

SourceOutletiGeneral editorial lean of the outletStoryiHow they covered this specific storyToneFactuality

index-hrcenter-leftcenterneutral—irrelevant content unrelated to pharmaceuticals

cnbccentercenter-lefturgentMostly Factualurgent market language emphasizing volatility

bloomberg

Coverage leans: center

Coverage maintains a predominantly market-focused, institutional tone typical of financial journalism, with minor variations in urgency and strategic emphasis reflecting standard business reporting rather than partisan ideology.

Sources

Showing 6 of 10 sources

ReutersVery High4h ago

Novartis faces fresh blow to pipeline with del-desiran drug setback - reuters.com

Novartis faces fresh blow to pipeline with del-desiran drug setback reuters.com

Read full article →

bloombergHigh46m ago

Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback

Novartis saw a treatment for a rare muscle-wasting disease fail a late-stage study, the third clinical-trial setback in a week. The medicine was the centerpiece of Novartis’s $12 billion takeover of Avidity Biosciences and raises questions about the drugmaker’s growth prospects. Fabienne Kinzelmann reports on Bloomberg Television. (Source: Bloomberg)

Read full article →

cnbcMostly Factual3h ago

Pharma major plummets over 10% after third trial disappointment in a week

Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.

Read full article →

morningstar5h ago

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial - Morningstar

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial Morningstar

Read full article →

seeking-alphaMixed2h ago

Novartis drops 13% on trial failure, dragging Dyne and Sarepta

Read full article →

investing-com2h ago

Why is Novartis stock tumbling today?

By Investing.com

Read full article →

Coverage Timeline

First report: morningstar · 8 Sept, 05:48|Full coverage: 10 · 4h|Window: 4h

Left-leaningCenterRight-leaning

morningstar8 Sept, 05:48First to report

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial - Morningstar

wsj8 Sept, 05:54

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial - WSJ

Reuters8 Sept, 06:05

Novartis faces fresh blow to pipeline with del-desiran drug setback - reuters.com

1h later

index-hr8 Sept, 07:28

Novartis drops 13% on trial failure, dragging Dyne and Sarepta

1h later

bloomberg8 Sept, 10:13Latest update

Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback

Story evolution

The narrative quickly evolved from a straightforward clinical update to a broader assessment of Novartis’s acquisition-driven growth model and near-term financial stability.

Initial DisclosureSept 8, 05:48–06:05 UTC

Reuters and WSJ publish breaking reports confirming the del-desiran trial missed its primary endpoint

Market ReactionSept 8, 07:28–08:41 UTC

Financial networks and exchanges report a sharp 10–13% share price drop as trading opens

Strategic & Sector AnalysisSept 8, 08:56–10:13 UTC

Outlets contextualize the miss against the $12B Avidity acquisition and note spillover effects on peer biotechs

Novartis Shares Plunge After Late-Stage Neuromuscular Drug Trial Fails

Why this matters

The Story

What sources agree on

Key claims4 agreed · 1 unverified

Where they diverge

Coverage gaps

Coverage matrix

The Story

Source Diversity

Source Diversity

Political spectrum

Sources

Novartis faces fresh blow to pipeline with del-desiran drug setback - reuters.com

Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback

Pharma major plummets over 10% after third trial disappointment in a week

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial - Morningstar

Novartis drops 13% on trial failure, dragging Dyne and Sarepta

Why is Novartis stock tumbling today?

Coverage Timeline

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial - Morningstar

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial - WSJ

Novartis faces fresh blow to pipeline with del-desiran drug setback - reuters.com

Brašno čuvate u originalnoj vrećici? Zašto to i nije najbolja ideja

Pharma major plummets over 10% after third trial disappointment in a week

Why is Novartis stock tumbling today?

Studie verfehlt Hauptziel: Mega-Absturz von Novartis-Aktie

Novartis shares slide after drug for muscular disease fails trial

Novartis drops 13% on trial failure, dragging Dyne and Sarepta

Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback

Story evolution

Related Stories

Samsung India Lays Off 100 Executives Amid Business Restructuring

EU Court Rules Against Belgian Far-Right Party in Ikea Dispute

China's August exports surge 25% as trade surplus widens

Manipuri musician beaten to death by delivery workers in Delhi over noise complaint

Why this matters

The Story

What sources agree on

Key claims4 agreed · 1 unverified

Where they diverge

Coverage gaps

Coverage matrix

Story evolution

Political spectrum